Immunome (NASDAQ:IMNM) Director Jean Jacques Bienaime Acquires 10,500 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 10,500 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were acquired at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the acquisition, the director owned 43,415 shares of the company’s stock, valued at $844,421.75. This trade represents a 31.90% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, May 15th, Jean Jacques Bienaime purchased 5,000 shares of Immunome stock. The shares were acquired at an average price of $20.70 per share, for a total transaction of $103,500.00.
• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The shares were acquired at an average price of $21.55 per share, for a total transaction of $21,550.00.

Immunome Stock Down 1.2%

IMNM stock opened at $18.39 on Wednesday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -7.73 and a beta of 2.04. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The company’s fifty day simple moving average is $21.95 and its 200 day simple moving average is $21.71.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Stephens dropped their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Leerink Partners dropped their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price on the stock. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Immunome presently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after acquiring an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Immunome during the fourth quarter worth about $30,710,000. Finally, Sofinnova Investments Inc. increased its position in shares of Immunome by 271.2% during the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after acquiring an additional 1,182,426 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.